Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).
Authors
- G. Kees Hovingh (ORCID: https://orcid.org/0000-0002-8145-1676)
- Silvio E. Inzucchi
- Rodica Pop‐Busui (ORCID: https://orcid.org/0000-0002-2042-1350)
- Nikolaus Marx (ORCID: https://orcid.org/0000-0001-6141-634X)
- Sharon L. Mulvagh (ORCID: https://orcid.org/0000-0002-7377-4053)
- Jens‐Peter David
- John Deanfield (ORCID: https://orcid.org/0000-0001-8806-6052)
- John B. Buse (ORCID: https://orcid.org/0000-0002-9723-3876)
- Johannes F.E. Mann (ORCID: https://orcid.org/0000-0002-3154-5332)
- Mette Gislum
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Neil R Poulter (ORCID: https://orcid.org/0000-0002-6292-997X)
- Maria Sejersten Ripa (ORCID: https://orcid.org/0000-0002-5491-6327)
- Stephen C. Bain (ORCID: https://orcid.org/0000-0001-8519-4964)
- Matthew A. Cavender (ORCID: https://orcid.org/0000-0002-4466-4760)
- Scott S. Emerson (ORCID: https://orcid.org/0000-0002-2695-0165)
- Kirstine Brown‐Frandsen
- Mads D.M. Engelmann
Institutions
- University of North Carolina at Chapel Hill (US)
- Parkland Health & Hospital System (US)
- Dalhousie University (CA)
- Oregon Health & Science University (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Novo Nordisk (Denmark) (DK)
- University of Washington (US)
- Yale University (US)
- Swansea University (GB)
- Universitätsklinikum Aachen (DE)
- KfH Kuratorium für Dialyse und Nierentransplantation (DE)
- University College London (GB)
- Imperial College London (GB)
- The University of Texas Southwestern Medical Center (US)
- RWTH Aachen University (DE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1056/nejmoa2501006
- Citations
- 220
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 284.89
Funders
- Novo Nordisk